GlassScriptPhysician profile
John D Vickery
NPI 1336364793
$12,144.09
in general payments reported to CMS, 2019-2025
36 companies · $4,229 in 2025
The $4,229 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $375 · 2021: $104 · 2022: $1,298 · 2023: $2,223 · 2024: $3,915 · 2025: $4,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,184 · Consulting Fee: $1,812 · Honoraria: $1,218 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,184.32 |
| Consulting Fee | $1,812.00 |
| Honoraria | $1,218.00 |
| Education | $153.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $1,825.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,578.67 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Blueprint Medicines Corporation | $1,568.10 | 2023-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $1,215.41 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,215.39 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,010.72 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $573.08 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Aimmune Therapeutics, INC. | $571.05 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $406.46 | 2023-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $315.17 | 2023-2025 | |
| Grifols USA, LLC | $286.04 | 2022-2025 | Xembify |
| Csl Behring | $228.57 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $221.16 | 2022-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $144.94 | 2023-2024 | |
| Optinose US, INC. | $104.34 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87.15 | 2022-2023 | Rinvoq |
| Pfizer INC. | $84.80 | 2022-2024 | |
| Kaleo, INC. | $80.83 | 2022-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $78.25 | 2025 | Neffy |
| Phadia US INC. | $66.80 | 2021-2024 | Immunocap |
| Ionis Pharmaceuticals, INC. | $64.86 | 2025 | Dawnzera |
| Leo Pharma INC. | $63.00 | 2022-2025 | Adbry |
| Teva Pharmaceuticals USA, INC. | $54.41 | 2022 | |
| Amgen INC. | $45.44 | 2024 | Tezspire |
| Genentech USA, INC. | $44.18 | 2024 | Xolair |
| Incyte Corporation | $27.27 | 2022 | |
| Cycle Pharmaceuticals INC | $25.02 | 2025 | Sajazir |
| Dermavant Sciences, INC. | $23.21 | 2024 | Vtama |
| Lilly USA, LLC | $21.01 | 2024 | Ebglyss |
| Hikma Pharmaceuticals USA | $19.65 | 2022 | |
| Greer Laboratories, INC. | $19.30 | 2023 | Palforzia |
| Galderma Laboratories, L.P. | $18.64 | 2025 | Nemluvio |
| Tersera Therapeutics LLC | $17.93 | 2023 | Quzyttir |
| Verona Pharma, INC. | $17.89 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $13.39 | 2024 | |
| Organon LLC | $6.57 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vickery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.